Leerink Partners Starts Cartesian Therapeutics (RNAC) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts RNAC Hot Sheet
Price: $6.41 --0%
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Leerink Partners analyst Thomas Smith initiates coverage on Cartesian Therapeutics (NASDAQ: RNAC) with a Outperform rating and a price target of $39.00.
For an analyst ratings summary and ratings history on Cartesian Therapeutics click here. For more ratings news on Cartesian Therapeutics click here.
Shares of Cartesian Therapeutics closed at $18.26 yesterday.
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Freedom Broker Starts Dole (DOLE) at Buy
- Goldman Sachs Assumes Skyworks Solutions (SWKS) at Sell
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
